Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials.

J Hematol Oncol · 2022 · PMC9124390 · PMID 35598026

Europe PMC DOI

hedged sentence

0.3900

closest p · 7.8× alpha

0.3900

boldest claim

The sentences

did not reach statistical significancep = 0.39not close (p > 0.1)

Although the risk of major bleeding was numerically higher with DOACs, this difference did not reach statistical significance (RR, 1.17, 95%CI, 0.82–1.67; p = 0.39; I 2 = 12%; Fig. 1 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.